Based on current WHO guidelines, the distinction between oligodendrogliomas and diffuse astrocytomas necessitates the detection of several molecular markers, primarily the IDH1/2 mutation status and whole arm 1p19q codeletion status.4 The gene discussed is IDH1; the disease is diffuse astrocytoma.